ORYZON Announces First Patient Dosed in Phase 1 Trial of the LSD1 inhibitor RG6016 in Small Cell Lung Cancer (SCLC)

BARCELONA, SPAIN and CAMBRIDGE MA.

• Second clinical trial with RG6016, while the first one in Acute Leukemia is almost completed

Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced that the first patient has been treated in the Phase I study of RG6016, a LSD1 inhibitor, in small cell lung cancer (SCLC). This clinical trial is executed by Roche.

Click here to see the full Press Release